In breast cancer, loss of PTEN or its downregulation by epigenetic mechanisms [180], frequent in the basal-like subtype [5,181,182] and leading to activation of the PI3K pathway, is associated with diminished responsiveness to MEK inhibitors [93]. The gene discussed is PTEN; the disease is breast carcinoma.